113 related articles for article (PubMed ID: 9226027)
1. OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease.
Cioffi M; Fratta M; Gazzerro P; Di Finizio B; Tucci A; Molinari AM
Tumori; 1997; 83(2):594-8. PubMed ID: 9226027
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
Bonfrer JM; Korse CM; Verstraeten RA; van Kamp GJ; Hart GA; Kenemans P
Clin Chem; 1997 Mar; 43(3):491-7. PubMed ID: 9068593
[TBL] [Abstract][Full Text] [Related]
3. Critical aspects of immunoradiometric thyroglobulin assays.
Ferrari L; Biancolini D; Seregni E; Aliberti G; Martinetti A; Villano C; Pallotti F; Chiesa C; Bombardieri E
Tumori; 2003; 89(5):537-9. PubMed ID: 14870780
[TBL] [Abstract][Full Text] [Related]
4. The second generation CA 125 assays.
Kenemans P; Verstraeten AA; van Kamp GJ; von Mensdorff-Pouilly S
Ann Med; 1995 Feb; 27(1):107-13. PubMed ID: 7741988
[TBL] [Abstract][Full Text] [Related]
5. Use of a second-generation CA125 assay in gynecologic patients.
Hornstein MD; Goodman HM; Thomas PP; Knapp RC; Harlow BL
Gynecol Obstet Invest; 1996; 42(3):196-200. PubMed ID: 8938474
[TBL] [Abstract][Full Text] [Related]
6. Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.
Fisken J; Leonard RC; Roulston JE
Dis Markers; 1989; 7(1):61-7. PubMed ID: 2653700
[TBL] [Abstract][Full Text] [Related]
7. Comparison of one first-generation and three second-generation methods for the determination of CA 125.
Martin MJ; Blockx PP
Int J Biol Markers; 1996; 11(1):36-9. PubMed ID: 8740640
[TBL] [Abstract][Full Text] [Related]
8. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125.
Kobayashi H; Tamura M; Satoh T; Terao T
Clin Biochem; 1993 Jun; 26(3):213-9. PubMed ID: 8330391
[TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of the Elecsys CA 125 II assay.
Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
[TBL] [Abstract][Full Text] [Related]
11. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of second generation CA 125 assays.
Cosmi EV; Atlante G; Donadio C; Mariani L; Barbati A
Eur J Obstet Gynecol Reprod Biol; 1995 Jan; 58(1):73-6. PubMed ID: 7758648
[TBL] [Abstract][Full Text] [Related]
13. A new luminescence immunoassay for thyrotropin using coated tubes: evaluation and comparison with immunoradiometric assay.
Pilo A; Zucchelli GC; Ferdeghini M; Masini S; Calvo S
J Biolumin Chemilumin; 1989 Jul; 4(1):185-90. PubMed ID: 2801211
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
15. Discordant serum CA 125 values in commercial immunoassays.
van Kamp GJ; Verstraeten AA; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):99-103. PubMed ID: 8365530
[TBL] [Abstract][Full Text] [Related]
16. Ciclesonide ( Byk Gulden).
Dent G
Curr Opin Investig Drugs; 2002 Jan; 3(1):78-83. PubMed ID: 12054077
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
18. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
20. Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
Yedema KA; Thomas CM; Segers MF; Doesburg WH; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1992 Dec; 47(3):245-52. PubMed ID: 1294413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
